{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Immatics N.V."},"Symbol":{"label":"Symbol","value":"IMTXW"},"Address":{"label":"Address","value":"PAUL-EHRLICH-STRAÃ¿E 15, TUBINGEN, 72076, Germany"},"Phone":{"label":"Phone","value":"+49 707153970"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.immatics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Cedrik M. Britten","title":"Chief Medical Officer"},{"name":"Evelyn Roth-Geissler","title":"Vice President & Global Head-Clinical Operations"},{"name":"Harpreet Singh-Jasuja","title":"Chief Executive Officer, Executive Director & MD"},{"name":"Steffen Walter","title":"Chief Operations Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}